Renowned medical oncologist shares key takeaways from ASCO 2026

Farshid Dayyani, MD, PhD shared his key takeaways on emerging developments in gastrointestinal oncology at ASCO 2026.

To summarize emerging developments in gastrointestinal oncology presented at ASCO 2026.

Study on Bispecific Antibodies: A study demonstrated bispecific antibodies achieving 80% response rates in gastric cancer.
Hepatocellular Carcinoma Trials: Phase three trial results reinforced the benefits of dual immune checkpoint inhibition followed by local-regional consolidation, showing clear progression-free survival advantages.
Neuroendocrine Carcinoma Findings: An antibody-drug conjugate targeting BCL-3 exhibited transformative 55–60% response rates in patients with high expression levels.
HER2 Testing Rates: Findings highlighted suboptimal HER2 testing rates despite the availability of targeted therapies, indicating a need for improved biomarker profiling in clinical practice.

Bispecific antibodies show 80% response rates in gastric cancer.
Dual immune checkpoint inhibition followed by local-regional consolidation improves progression-free survival in hepatocellular carcinoma.
An antibody-drug conjugate targeting BCL-3 has 55–60% response rates in neuroendocrine carcinoma.
Suboptimal HER2 testing rates exist despite available targeted therapies.